Trigemina
Moraga
About Trigemina
Trigemina, Inc. develops non-opiate drug formulations and delivery systems for the pain therapy. The company’s products include TI-001, an intranasal oxytocin that targets chronic and sub-acute head pain; and TI-002, a non-opioid treatment that addresses a range of pain, including neuropathic pain throughout the body. Its drugs are delivered via the nasal-cerebral pathway. The company was founded in 2006 and is based in Mountain View, California.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $27.6M
- Funding stage: Early Stage Venture
- Last round: Series A (Jul 2017)
- Website: trigemina.com
- Phone: 925-377-0664
Industries & Categories
Biotechnology, Medical
Social Profiles
Canonical: https://fsome.com/organization/trigemina-151221 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.